What happened
ATTAIN-OSA evaluates orforglipron for obstructive sleep apnea, with clinical results pending.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward ATTAIN-OSA's result, from named public quotes (n=0). As of Oct 22, 2026.
Orforglipron for the treatment of obstructive sleep apnea: results from ATTAIN-OSA
Orforglipron for the treatment of obstructive sleep apnea: results from ATTAIN-OSA. Session: LBS.05. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
No takes yet. Share an insight, caveat, or question.
Calamai et al. (2026) studied this question. Orforglipron was evaluated for the treatment of obstructive sleep apnea in the ATTAIN-OSA trial, with clinical results currently pending.